Cytek Biosciences, Inc.
CTKBNasdaqHealthcare · Laboratory Analytical Instruments · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M | $92.8M |
| Operating income | −$40.4M | −$20.5M | −$27.8M | −$1.8M | $9.2M | $13.7M |
| Net income | −$66.5M | −$6.0M | −$12.1M | $2.5M | $3.0M | $19.4M |
| Total assets | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M | $220.0M |
| Total liabilities | $119.8M | $103.8M | $101.4M | $93.9M | $57.9M | $41.7M |
| Equity | $341.7M | $395.7M | $393.1M | $425.5M | $405.4M | −$16.0M |
| EPS (diluted) | — | — | $-0.09 | $0.02 | $0.00 | $0.10 |
| Shares out. | 128.1M | 130.8M | 135.4M | 134.1M | 133.7M | 31.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −20.0%
- Net margin
- −33.0%
- Return on equity
- −19.5%
- Return on assets
- −14.4%
- Return on capital (ROCE)
- −10.5%
- Liabilities / assets
- 26.0%
- Debt / equity
- 0.35×
- Book value / share
- $2.67
- Revenue growth (YoY)
- 0.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 6.15safe
- Accruals / assets
- −13.4%clean
- Beneish M-Score
- -3.33normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 4 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 1, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 13, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Millennium Management LlcPassive (13G)May 18, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Topline Capital Management, LlcPassive (13G)Nov 17, 2025
- Brown Capital Management LlcPassive (13G)Nov 12, 2025
- Blackrock, Inc.Passive (13G)Jul 18, 2025
- Ra Capital Management, L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.9M | 6.0 | -11.3% |
| Apr 30, 2026 | 7.7M | 12.4 | -4.4% |
| Apr 15, 2026 | 8.1M | 17.2 | +0.5% |
| Mar 31, 2026 | 8.1M | 10.8 | +6.5% |
| Mar 13, 2026 | 7.6M | 8.6 | +3.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Results of operationsFeb 26, 2026
- Results of operationsJan 13, 2026
- Results of operationsNov 5, 2025
- Results of operationsAug 6, 2025
- Shareholder voteJun 24, 2025
- Results of operationsMay 8, 2025
- Results of operationsFeb 27, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.